(Press-News.org) After the smoking ban was introduced in Bremen, Germany, the rate of ST-elevation myocardial infarction (STEMI) diminished by 26% in non-smokers but remained almost constant in active smokers, according to research presented today at the ESC Congress 2012. The results were presented by Dr Johannes Schmucker from Germany.
Many European countries have passed anti-smoking legislation which bans smoking from restaurants, bars and public buildings. After implementation of such a smoking ban on 1 January 2008 in the metropolitan area of Bremen in northwest Germany (800,000 inhabitants) a 16% decline in ST-elevation myocardial infarction (STEMI) was observed. STEMI is the severest form of myocardial infarction.
For the study, 3,545 STEMIs in the Bremen-STEMI-Registry which occurred between 2006 and 2010 were analyzed. Figure 1 shows the average number of STEMIs per month in the total population, smokers and non-smokers in 2006-2007 and 2008-2010. Dr Schmucker said: "There were more non-smokers than smokers, which explains why the non-smokers group had more STEMIs registered."
For the total population in 2006 and 2007, before the smoking ban was passed, averages of 65 STEMIs were registered per month. In 2008 to 2010, after the smoking ban was passed, the number fell by 16% to an average of 55 STEMIs per month. "This confirms that the smoking ban had a positive impact on the population as a whole by decreasing the number of STEMIs," said Dr Schmucker.
A nearly constant rate of STEMIs was observed in active smokers during 2006-2010. In 2006-2007 active smokers had an average of 25 STEMIs per month. In 2008-2010, they had an average of 26 STEMIs per month, a 4% increase. Dr Schmucker said: "Active smokers are inhaling such high doses of tobacco smoke that being exposed to less passive smoke in public venues is not going to change the risk for that particular group."
In non-smokers there was a 26% decrease in STEMIs, from an average of 39 STEMIs per month in 2006-2007 to an average of 29 STEMIs per month in 2008-2010. The steepest decline in the non-smoking group was detected in young non-smokers; in this group the average number of STEMIs per month was 31% lower in 2008-2010 compared to 2006-2007.
"The reduction in the occurrence of this severest and deadliest form of myocardial infarction in the metropolitan area of Bremen can be partially attributed to the commencement of anti-smoking legislation," said Dr Schmucker. "Non-smokers and especially non-smokers under the age of 65 benefited most from the implementation of the law, indicating the harmful effects of passive smoking. This suggests that expanding anti-smoking legislation could reduce the occurrence of STEMIs even further in the future."
###
Contributors:
J. Schmucker1, H. Wienbergen1, S. Seide1, E. Fiehn1, A. Fach1, R. Hambrecht1
1Hospital Links der Weser, Department of Cardiology and Angiology, Bremen, Germany
Notes to editors
About the European Society of Cardiology www.escardio.org
The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2012
The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available here.
More information is available from the ESC Press Office at press@escardio.org.
Non-smokers benefit most from smoking ban
2012-08-27
ELSE PRESS RELEASES FROM THIS DATE:
Adolescent smokers have artery damage
2012-08-27
Adolescent smokers have thicker artery walls indicative of early development of atherosclerosis, according to research presented today at the ESC Congress. The findings from the Sapaldia Youth Study were presented by Dr Julia Dratva from Switzerland.
Early exposure to tobacco smoke is associated with various adverse health outcomes in children and adolescents, including low birth weight and impaired lung growth and function. Tobacco smoke is considered highly atherogenic in adults, but little is known about the impact of tobacco smoke exposure on cardiovascular health ...
Heart separation device improves 3 year outcomes in heart failure patients
2012-08-27
Munich, Germany – A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves 3 year outcomes in patients with ischemic heart failure, according to research presented at the ESC Congress 2012. The findings were presented by Professor William T. Abraham at an ESC press conference on 25 August and by Dr Marco Costa at an ESC Congress scientific session on 27 August.
Heart failure is a common, debilitating, and potentially deadly condition in which the heart is unable to supply sufficient blood flow to meet the needs ...
Promising new drug target discovered for treatment and prevention of heart failure
2012-08-27
Munich, Germany – A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.
According to the US Centers for Disease Control and Prevention, about 5.8 million Americans suffer from heart failure and 670,000 new cases are diagnosed each year. One in five people with heart failure die within one year of diagnosis. Heart failure is most often treated with aggressive ...
Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack
2012-08-27
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet.
For more than a million Americans ...
The PURE study
2012-08-27
Munich, Germany – Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries.
Results from the Prospective Urban Rural Epidemiology (PURE) study were reported here today by Professor Salim Yusuf of the Population Health Research Institute, McMaster University and Hamilton Health Sciences, in Hamilton, Canada and principal investigator of the study. The study,
involving 154,000 individuals from 628 communities, ...
The DeFACTO study
2012-08-27
Munich, Germany – Data presented today from the prospective Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study show that, when compared to standard coronary angiography (CT), the non-invasive assessment of fractional flow reserve by computed tomography (FFRct) provides a more accurate determination of which lesions require invasive evaluation.(1)
The results of the study were presented by Dr James K. Min, director of Cardiac Imaging Research and co-director of Cardiac Imaging at the Department of Medicine, Imaging and ...
Median follow-up results from the ALTITUDE study, stopped prematurely in December 2011
2012-08-27
Munich, Germany – Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) blockade in type 2 diabetics at high risk of cardiovascular and renal events, according to Professor Hans-Henrik Parving from Rigshospitalet, University of Copenhagen, Denmark. Presenting results from the study today, he said the treatment "may even be harmful".
The ALTITUDE trial was stopped prematurely in December 2011 on recommendation ...
The TRILOGY ACS study
2012-08-27
Munich, Germany – The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke.
The findings, from the phase III Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) study, were presented today at a Hot Line session of ESC Congress 2012 in Munich.
TRILOGY ACS was double-blind, randomised trial ...
The PARAMOUNT study
2012-08-27
Munich, Germany – The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial.
Approximately half of all heart failure patients have normal or nearly normal ejection fraction, a measure of their strength of cardiac contraction. However, while many studies have shown a benefit of pharmacological therapies in heart failure ...
The Aldo-DHF study
2012-08-27
Munich, Germany – Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.
Behind his conclusion lay results showing that mineralocorticoid receptor blockade with spironolactone improves cardiac function and structure, reduces neuroendocrine activation, and effectively reduces blood pressure in a patient population with symptomatic predominantly ...